Home Members Tools Credit Cards
   

RIGL Stock Quote and Technical Analysis

Portfolios Markets Resources
  Symbol List
Rigel Pharmaceuticals, Inc. (RIGL)
▼ 3.21 (-0.21) -6.14%
Open: 3.42
High: 3.46
Low: 3.205
Afterhours: N/A - N/A
Volume: 387685
4/23/2014 4:00pm
 
Interactive Chart
EPS: -1.02 (Current Year Estimated: -1.06)
Dividend: N/A
P/E: N/A

Technicals:
52 Week Range: 2.31 - 5.00
50 Day Moving Average: 3.8767
200 Day Moving Average: 3.2534
Pivot Point (Next Trading Session): 3.29

Login or signup free to Add "RIGL" to your portfolio

Resources:

News:


Is Rigel Pharmaceuticals (RIGL) Stock a Solid Choice Right Now?
Fri, 11 Apr 2014 11:00:13 GMT


RIGEL PHARMACEUTICALS INC Files SEC form 8-K, Change in Directors or Principal Officers
Fri, 21 Mar 2014 20:16:25 GMT


Why VAALCO Energy, Rigel Pharmaceuticals, and Companhia Siderurgica Nacional Are Today's 3 Best Stocks
Fri, 14 Mar 2014 21:16:14 GMT


RIGEL PHARMACEUTICALS INC Financials
Wed, 12 Mar 2014 17:04:11 GMT


Rigel (RIGL) Worth Watching: Stock Rises 10.2%
Fri, 07 Mar 2014 12:37:07 GMT


Why Rigel Pharmaceuticals, Inc. Shares Popped
Thu, 06 Mar 2014 18:51:59 GMT


Top Stories in Biotech This Morning: Pluristem Therapeutics, Inc, Rigel Pharmaceuticals, Inc. and Sangamo Biosciences, Inc.
Thu, 06 Mar 2014 13:49:57 GMT


Rigel Rises on Narrower Q4 Loss
Thu, 06 Mar 2014 13:40:06 GMT


Rigel Announces Publication of R118 AMPK Activator Research
Thu, 06 Mar 2014 13:15:23 GMT
[at noodls] - SOUTH SAN FRANCISCO, Calif., March 6, 2014 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced that the American Journal of Physiology has published recent research results with ...

Rigel Announces Publication of R118 AMPK Activator Research
Thu, 06 Mar 2014 12:30:00 GMT
[PR Newswire] - SOUTH SAN FRANCISCO, Calif., March 6, 2014 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (RIGL) today announced that the American Journal of Physiology has published recent research results with its orally-bioavailable AMPK activator, R118. The publication, entitled "Exercise performance and peripheral vascular insufficiency improve with AMPK activation…", provides strong preclinical evidence that R118 may be useful in treating peripheral artery disease (PAD), a chronic and progressive vascular disease effecting nearly 5% of the population over the age of 50, and related metabolic disorders. This publication extends work from a previous Rigel publication on the mechanism and impact of AMPK activation. The Company also announced that it has commenced Phase 1 clinical studies with R118 as a potential treatment for Intermittent Claudication (IC), a painful and debilitating outcome of PAD.

RIGEL PHARMACEUTICALS INC Files SEC form 8-K, Change in Directors or Principal Officers
Wed, 05 Mar 2014 22:31:30 GMT


RIGEL PHARMACEUTICALS INC Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and
Tue, 04 Mar 2014 21:32:50 GMT


RIGEL PHARMACEUTICALS INC Files SEC form 10-K, Annual Report
Tue, 04 Mar 2014 19:01:45 GMT


Rigel Announces Fourth Quarter and Year End 2013 Financial Results
Tue, 04 Mar 2014 14:49:10 GMT
[at noodls] - SOUTH SAN FRANCISCO, Calif., March 4, 2014 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq:RIGL) today reported financial results for the fourth quarter and year ended December 31, 2013. ... This is ...

Rigel Announces Fourth Quarter and Year End 2013 Financial Results
Tue, 04 Mar 2014 12:30:00 GMT
[PR Newswire] - SOUTH SAN FRANCISCO, Calif., March 4, 2014 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq:RIGL) today reported financial results for the fourth quarter and year ended December 31, 2013. For the fourth ...

Rigel Announces Participation at Two Investor Conferences
Thu, 27 Feb 2014 13:31:43 GMT
[at noodls] - SOUTH SAN FRANCISCO, Calif., Feb. 27, 2014 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced that company management will present at two upcoming investor conferences. Details ...

Rigel Announces Participation at Two Investor Conferences
Thu, 27 Feb 2014 12:30:00 GMT
[PR Newswire] - SOUTH SAN FRANCISCO, Calif., Feb. 27, 2014 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced that company management will present at two upcoming investor conferences. Details ...

Rigel Announces Participation at Two Investor Conferences
Thu, 06 Feb 2014 12:45:45 GMT
[at noodls] - SOUTH SAN FRANCISCO, Calif., Feb. 6, 2014 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced that James M. Gower, the company's chairman and chief executive officer, is scheduled ...

Rigel Announces Participation at Two Investor Conferences
Thu, 06 Feb 2014 12:30:00 GMT
[PR Newswire] - SOUTH SAN FRANCISCO, Calif., Feb. 6, 2014 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced that James M. Gower, the company's chairman and chief executive officer, is scheduled ...

RIGEL PHARMACEUTICALS INC Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and
Fri, 10 Jan 2014 21:16:13 GMT


All Company News is Powered by Yahoo! Finance

 

 

 

Credit Cards | Finance Social Network | Credit Card Reviews | Markets
About Us | FG on the Web | Sitemap | Privacy | Terms | Contact


Copyright © 2014 Finance Globe. All rights reserved.